Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

China · Delayed Price · Currency is CNY

61.88

-3.11 (-4.79%)

Aug 21, 2026, 3:00 PM CST

-27.93% (1Y)

Market Cap	25.26B -27.7%
Revenue (ttm)	4.02B +28.2%
Net Income	1.08B +13.5%
EPS	2.63 +12.9%
Shares Out	408.19M
PE Ratio	23.54
Forward PE	18.24
Dividend	0.62 (1.03%)
Ex-Dividend Date	May 29, 2026

Volume	8,361,454
Open	63.41
Previous Close	64.99
Day's Range	60.88 - 63.99
52-Week Range	50.00 - 89.65
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1996

Employees 3,644

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688278

Full Company Profile

Financial Performance

In 2025, Xiamen Amoytop Biotech's revenue was 3.70 billion, an increase of 31.18% compared to the previous year's 2.82 billion. Earnings were 1.03 billion, an increase of 24.61%.

Financial Statements